The Journal of investigative dermatology
Lenabasum, a cannabinoid type 2 receptor agonist, exerts anti-inflammatory effects in Dermatomyositis.
DeAnna Diaz, Thomas Vazquez, Nilesh Kodali, Muhammad M Bashir, Madison Grinnell, Rohan Dhiman, Emily Keyes, Joshua Dan, Julianne Kleitsch, Caroline J Stone, Victoria P Werth
Published: 202610.1016/j.jid.2025.12.020
Abstract
Dermatomyositis (DM) is an autoimmune disease classically affecting the skin, muscles, and lungs. Patients with DM have poor quality of life and current treatments fail to work in half of DM patients. There is a need for an effective and safer therap…
Preview only. Read the full abstract at the source